Overview
Overview
Highly cytotoxic innate immune lymphocytes derived from UCT-WJ-MSC lineage differentiation; capable of destroying tumor cells, virally infected cells, and senescent cells without MHC restriction
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Source & Manufacturing |
|---|
| Derived from P2 UCT-WJ-MSCs via NK cell differentiation |
| SCF IL-3 (hematopoietic progenitor induction) → IL-7 IL-15 Flt3L (NK cell commitment and expansion) |
| DMSO-free cryopreservation |
| Post-thaw viability 95% |
| Markers: CD56⁺, CD16⁺, NKG2D⁺, NKp30⁺, NKp46⁺, NKG2A⁺/KIR (variable) |
| Cytotoxicity assay (K562 lysis 40% at 10:1 E:T ratio) confirms killing competence prior to release |
| HLA-DR⁻ confirms immune-privileged status for allogeneic use |
Clinical Overview
Clinical Overview
Natural Killer (NK) cells are cytotoxic lymphocytes of the innate immune system that destroy abnormal cells (tumor cells, virally infected cells, and senescent cells) without requiring prior sensitization or antigen presentation — a critical advantage over T-cell-based therapies that require patient-specific HLA matching. Akira NK Cells derived from UCT-WJ-MSCs are more naive, less exhausted, and more proliferatively competent than adult peripheral blood NK cells — reflecting the developmental advantage of perinatal origin. They express high levels of activating receptors (NKG2D, NKp30, NKp46) that detect stress ligands (MICA, MICB, ULBP) on tumor and senescent cells, triggering lysis via perforin/granzyme B release. The anti-aging application exploits NK cells' ability to selectively eliminate SASP-producing senescent cells (which express NKG2D ligands), reducing systemic inflammatory burden and potentially decelerating tissue aging.
Process
Mechanism of Action
Cytotoxic Killing via Perforin/Granzyme B: Activating receptor engagement (NKG2D, NKp30, NKp46) triggers immunological synapse formation, directional degranulation of perforin (pore-forming) and granzyme B (serine protease), initiating caspase-dependent apoptosis in target cells. Killing is MHC-unrestricted — no HLA matching needed.
ADCC (Antibody-Dependent Cellular Cytotoxicity): CD16 (FcγRIII) engagement by antibody-coated tumor cells triggers NK-mediated lysis — directly applicable in combination with therapeutic antibodies (trastuzumab, rituximab) for synergistic anti-tumor effect.
Fas/FasL Pathway: NK cells express FasL (CD178), inducing Fas-mediated apoptosis in Fas+ tumor and senescent cells via the extrinsic apoptosis pathway.
Senescent Cell Clearance (Senolytic): Senescent cells upregulate NKG2D ligands (MICA, ULBP2, NKG2DL) as part of SASP — making them selectively vulnerable to Akira NK cell killing. This reduces SASP-driven systemic inflammation and tissue degeneration associated with aging.
CAR-NK Platform Compatibility: Akira NK Cells are platform-ready for CAR (Chimeric Antigen Receptor) engineering with tumor-specific CARs (CD19-CAR, HER2-CAR, EGFR-CAR), enabling next-generation targeted anti-cancer products with retained allogeneic applicability.
Biomarkers
Key Biomarkers & Molecular Cargo
| Marker / Molecule | Functional Role |
|---|---|
| CD56 / CD16 | NK cell identity (CD56) and ADCC receptor (CD16/FcγRIII) |
| NKG2D | Primary activating receptor detecting stress ligands on tumor/senescent cells |
| NKp30 / NKp46 | Natural cytotoxicity receptors; tumor antigen-independent killing |
| Perforin / Granzyme B | Cytotoxic granule components; pore formation and caspase activation |
| FasL (CD178) | Extrinsic apoptosis pathway trigger on NK cell surface |
| miR-155 / miR-223 | NK cell function-regulating miRNAs carried in NK exosomes |
| TRAIL | TNF-related apoptosis-inducing ligand; additional NK-mediated killing pathway |
| IFN-γ | Potent anti-tumor cytokine secreted by activated NK cells; immunomodulation |
Applications
Therapeutic Applications
- Hematologic Malignancies (Leukemia, Lymphoma) — direct NK cytotoxicity
- Solid Tumors (Lung, Breast, Liver, Prostate, Colon) — NKG2D ligand-targeted killing
- Ovarian Cancer, Melanoma — elevated NKG2DL expression makes these highly susceptible
- Viral Infections (HIV, Hepatitis B/C, HPV, CMV) — NK-mediated viral control
- CAR-NK Platform (CD19, HER2, EGFR-targeted) — next generation targeted cellular therapy
- Anti-Aging Protocols — senescent cell clearance, SASP reduction
- Autoimmune Hepatitis / Scleroderma — NK immunomodulation
- Post-cancer immune reconstitution — NK-based immune surveillance restoration
Evidence
Clinical & Preclinical Evidence
A 2023 systematic review (IJMS, PMC9964266) of NK-derived extracellular vesicles in cancer immunotherapy confirmed that NK exosomes carry cytotoxic proteins (granzyme B, perforin), FasL, and TRAIL capable of inducing apoptosis in tumor cells in vitro and in vivo — demonstrating the dual cell exosome anti-tumor platform available from Akira NK Cells.[1]
A 2024 Cancer Molecular Targets review (PMC11218398) detailed that NK cell-derived exosomes (carrying granzyme B, miR-155/miR-223) demonstrated tumor cytotoxicity against leukemia, lymphoma, and solid tumor lines with superior safety profiles compared to NK cell infusion — confirming the mechanism of Akira NK Exosomes.[2]
UCT-derived NK cells demonstrate significantly higher naive:memory ratio, greater proliferative capacity in response to IL-15/IL-2, and 40–60% higher cytotoxicity in K562 lysis assays vs adult peripheral blood NK cells at matched passage — validating the quality advantage of perinatal origin.
For anti-aging applications, studies have confirmed that NK cells selectively kill p16+/p21+ senescent fibroblasts while sparing proliferating cells via NKG2D/ULBP2 axis — reducing SASP markers (IL-6, IL-8, MMP-3) in conditioned media and improving tissue regeneration in aged mouse models.
Phase I clinical trial data of allogeneic UCB-derived NK cell infusions in AML patients (MD Anderson) confirmed safety, transient engraftment, and anti-leukemic activity — directly supporting the clinical precedent for UCT-derived NK cell use in oncology.[3]